

33rd ANNUAL MEETING - AAS

of the
Austrian Atherosclerosis Society



May 8 – 9, 2026
Grundlsee

www.aas.at

General Information



Organizing committee:

Florian Kronenberg

Johanna Schachtl-Riess

Program committee:

Florentina Porsch

Johanna Schachtl-Riess

Nemanja Vujic

Venue:

Mondi Hotel

Archkogel 31, 8993 Grundsee

Congress office, Registration & Sponsoring:



Medizinische Ausstellungs- und Werbegesellschaft

Freyung 6, 1010 Wien

Tel.: +43-1-536 63-37

Email: maw@media.co.at

Web: www.maw.co.at

AAS – Society office:

AAS – Austrian Atherosclerosis Society

c/o MAW

ZVR-Zahl: 179890279

Contact: Katrin Doppler

Freyung 6, 1010 Wien

Tel.: +43-1-536 63-37

Email: aas@media.co.at

Web: www.aas.at

Registration link: <https://registration.maw.co.at/aas2026>

Dear colleagues and friends,

On behalf of the Executive Committee and the Program Committee, we would like to cordially welcome you to the 33rd Annual Meeting of the Austrian Atherosclerosis Society (AAS), which takes place at the hotel Mondi at Grundlsee on May 8 and 9, 2026. We are all very excited and looking forward to an interesting conference at this beautiful location.

The topics presented by our invited speakers include “Atherogenic lipid traits and risk of dementia – insights from genomics and causal inference” (Ruth Frikke-Schmidt, Copenhagen, Denmark), “Towards clinical utility of polygenic risk scores for atherosclerotic cardiovascular diseases” (Michael Inouye, Cambridge, UK), and “Harnessing the immune system for the treatment of atherosclerotic cardiovascular disease” (Ziad Mallat, Cambridge, UK). Another highlight is the presentation of the brand-new “Austrian Lipid Consensus 2026” to which many of our Austrian colleagues have contributed.

The members of our program committee (Johanna Schachtl-Riess, Florentina Porsch and Nemanja Vujic) have put together a very stimulating program around the lectures by our invited speakers. As in previous years, the presentations of recent research results by congress participants will form an essential part of the program. Our meeting offers all the opportunity to present and discuss your research findings in a nice and relaxed setting, listen to experts in the field, socialize and have fun.

12 DFP points have been requested for this event.

We would especially like to thank our sponsors, without whom it would not be possible to hold our annual meeting.

We are looking forward to an exciting conference and to your participation.



Univ.-Prof. Dr. Florian Kronenberg
President AAS



Johanna Schachtl-Riess, PhD
Secretary AAS

Organizational Matters



Our partner MAW (Katrin Doppler) is again in charge for the congress organization and on-site support which we very much appreciate.

Our congress will be held in the room Eugenia-Schwarzwald; appropriate signs will guide you there.

We kindly ask you to pay your contribution towards expenses in cash on site (AAS members € 130.–, non-members € 240.–). The annual AAS membership is also to be paid in cash on site at the registration desk (regular members € 60.–, students € 30.–).

For AAS members who are presenters (talk or poster) as well as a further AAS member listed on the abstract, the AAS will cover the costs of accommodation from May 8-9, 2026. Other members who are not falling under these rules and who have no grants or other financial support can reach out to the AAS Executive Committee asking for support under certain conditions. Further costs such as drinks from the mini-bar or other consumptions must be paid individually.

Presentations: 10 minutes plus 5 minutes for discussion (be sure to stay on schedule). Please bring your presentation on a USB drive at the latest in the break before your session.

Posters: please remove your poster by noon on Saturday, May 9, 2026. Otherwise your poster will be disposed of.

Abstract: for sustainability reasons, the abstract book will no longer be provided in printed form. Confirmed congress delegates may download the individual abstracts for personal use until July 31, 2026. Please note that forwarding or modifying the content is not permitted.

12:00 – 12:40	Opening lunch (registration required)
12:40 – 12:45	Welcome from the AAS President
12:45 – 14:30	Session 1: Biomarkers to Modulators: Immune Mechanisms and Therapeutic Frontiers in Atherosclerotic Cardiovascular Disease Chair: Dimitris Tsiantoulas
12:45 – 13:30	Keynote lecture 1 Ziad Mallat Cambridge, United Kingdom <i>Harnessing the immune system for the treatment of atherosclerotic cardiovascular disease</i>
13:30 – 13:45	Viktoria Juhasz Medical University of Vienna <i>Targeting APRIL improves the heart function after acute myocardial infarction</i>
13:45 – 14:00	Kamil Mieczkowski Medical University of Vienna <i>Evaluating a functional cross-talk between psoriasis and atherosclerosis</i>
14:00 – 14:15	Egon Demetz Medical University of Innsbruck <i>Inhibition of Lipocalin-2 promotes Kupffer cell-driven LDL clearance and reduces atherosclerosis</i>
14:15 – 14:30	Lea Rief Medical University of Vienna <i>Classic autoantibodies associate with necrotic core formation in mice and predict cardiovascular events in non-autoimmune coronary artery disease patients</i>
14:30 – 14:45	Coffee Break and Exhibition

- 14:45 – 16:15** **Session 2: Mendelian Randomization and Atherogenic Lipids across Brain and Heart**
Chair: Claudia Lamina
- 14:45 – 15:30** **Keynote lecture 2**
Ruth Frikke-Schmidt
Copenhagen, Denmark
Atherogenic lipid traits and risk of dementia – insights from genomics and causal inference
- 15:30 – 15:45** **Johanna F. Schachtl-Riess**
Medical University of Innsbruck
Mendelian randomization reveals interleukin-6 receptor-Lipoprotein(a) interplay with independent cardiovascular risk reductions
- 15:45 – 16:00** **Clemens Engler**
Medical University of Innsbruck
Elevated levels of lipoprotein(a) predict impaired long-term outcomes following cardiac surgery
- 16:00 – 16:15** **Johannes Bernhard**
Medical University of Vienna
Genotype-specific LDL-cholesterol-lowering responses and their diagnostic implications in severe hypercholesterolemia
- 16:15 – 16:30** **Meeting Photo, Coffee Break and Exhibition**

16:30 – 18:00	Session 3: From Consensus to Mechanism: Cellular Lipid Homeostasis from Adipocytes to Macrophages and Liver Chair: Dagmar Kratky
16:30 – 17:00	<i>Austrian Lipid Concensus</i> Florian Kronenberg, Florian Höllerl, Helmut Brath, Gersina Rega-Kaun
17:00 – 17:15	Elisabeth Ableitner University of Graz <i>Adipocyte ATGL deficiency reprograms monocyte fate and limits atherosclerosis</i>
17:15 – 17:30	Lukas Schmidt Medical University of Vienna <i>Proteomic effects of genetic and therapeutic PCSK9 inhibition</i>
17:30 – 17:45	Suravi Mukherjee Medical University of Graz <i>Secreted lysosomal acid lipase compensates for macrophage LAL loss and prevents lipid dysregulation in mice</i>
17:45 – 18:00	Máté Kiss Medical University of Vienna <i>Site-specific decline in overall hematopoietic capacity distinguishes the skull from long bones in response to hypercholesterolemia</i>
18:00 – 20:00	Poster Session and Drinks
18:00 – 19:30	AAS Board Meeting
20:00 – 22:00	Dinner and AAS Social Evening

- 08:45 – 10:30** **Session 4: Data-driven integrative risk stratification for ASCVD**
Chair: Christoph Binder
- 08:45 – 09:30** **Keynote lecture 3**
Michael Inouye
Cambridge, United Kingdom
Towards clinical utility of polygenic risk scores for atherosclerotic cardiovascular diseases
- 09:30 – 09:45** **Claudia Lamina**
Medical University of Innsbruck
Polygenic and clinical risk scores modify the impact of elevated Lp(a) on cardiovascular risk in CKD
- 09:45 – 10:00** **Silvia Di Maio**
Medical University of Innsbruck
Integrating variable number tandem repeats into association and fine-mapping for Lipoprotein(a)
- 10:00 – 10:15** **Roland Jäger**
Medical University of Vienna
Impact of clonal hematopoiesis on mortality across the spectrum of coronary artery disease
- 10:15 – 10:30** **Simon Aberger**
Medical University of Graz
Data-driven clustering of secretory bone and inflammatory markers to sub-phenotype hemodialysis patients
- 10:30 – 10:50** **Coffee Break & Exhibition**

10:50 – 12:20 Session 5: Novel therapeutic avenues across the cardiovascular disease spectrum

Chair: Marion Mußbacher

10:50 – 11:05 Irena Yordanova

Medical University of Vienna

SenomiR34 treatment to combat cardiovascular aging and atherosclerosis

11:05 – 11:20 Jonas Eder

Medical University of Innsbruck

The Role of HIF2 α in endothelial to mesenchymal transition

11:20 – 11:35 Vanessa Heim

Medical University of Innsbruck

Colchicine prevents intimal hyperplasia in venous bypass grafts

11:35 – 11:50 Melissa Zenker

Medical University of Vienna

Targeting non-canonical APRIL limits abdominal aortic aneurysm

11:50 – 12:05 Gülsüm Yilmaz Lauber

Medical University of Vienna

Deciphering the modulatory effect of OSE IgM in mouse model of cardiac damage

12:05 – 12:20 Dominik Hau

Medical University of Innsbruck

Antiretroviral therapy prevents aortic valve calcification after radiation

12:20 – 12:30 Bio Break

12:30 – 13:25 **Final Session: FH Registry Update,
Closing Remarks & General Assembly**
Chair: Florian Kronenberg

12:30 – 12:40 *Austrian Familial Hypercholesterolaemia (FH)
Registry - Annual Data Update (Azin Kheirkhah)*

12:40 – 12:55 *Prizes - with kind support of **

12:55 – 13:05 *Closing remarks*

13:05 – 13:25 *AAS general assembly (members only)*

13:25 – 14:30 **Closing lunch (registration required)**

** Prizes - with kind support of*



A. MENARINI PHARMA



The following posters will be shown:

- 1 **Adamidis Petros-Spyridonas**, University of Ioannina, Ioannina, Greece
Hypolipidemic treatment and neutrophil extracellular traps: the effect of lipid-lowering regimen on circulating myeloperoxidase-dna complexes and neutrophil stimulation
- 2 **Adamidis Petros-Spyridonas**, University of Ioannina, Ioannina, Greece
The effect of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists on circulating myeloperoxidase-dna (mpo-dna) complexes and neutrophil stimulation
- 3 **Diaz Malena**, Medical University of Graz
Consequences of lysosomal acid lipase overexpression on atherosclerosis
- 4 **Ondracek Anna**, Medical University of Vienna
Early changes in plasma eicosanoid profiles and oxidized lipids in the course of proprotein convertase subtilisin-kexin type 9 inhibition
- 5 **Höllerl Florian**, Klinik Landstraße, Vienna
Bariatric surgery leads to a significant reduction in triglyceride-rich lipoproteins and is associated with improved glycemic control
- 6 **Ioannou-Nikolaïdou Maria**, Medical University of Innsbruck
A novel regulator of cardiac reverse remodelling
- 7 **Katashynska Daryna**, Medical University of Vienna
Low variant allele frequency myeloid-specific Tet2 deficiency is insufficient to accelerate atherosclerosis
- 8 **Muller Lynn**, Medical University of Innsbruck
"Epigenetically Programmed Inflammation in Aortic Valve Stenosis: The Role of Trained Immunity"
- 9 **Winter-Pözl Leo**, Medical University of Innsbruck
Using CK-MB and hs-cTnT to Predict 30-Day Mortality After CABG: A Combined Rule-Out Approach
- 10 **Probst Clara**, Medical University of Vienna
Establishment of a human liver organoid to monitor lipoprotein uptake
- 11 **Zupcic Ana**, Medical University of Vienna
B cell-specific gilz signalling modulates myocardial infarction-accelerated atherosclerosis
- 12 **Dieplinger Hans**, Medical University of Innsbruck
ApoC-III deficiency caused by a splice variant in apoC3 is associated with an atheroprotective lipid profile but lower cholesterol efflux
- 13 **Deroissart Justine**, Medical University of Vienna
IgM profiling reveals circulating and plaque reactivity patterns linked to atherosclerosis progression
- 14 **Schooltink Laszlo**, Medical University of Graz
Characterization of acLIP – an underrecognized player in lipid metabolism
- 15 **Seeberger David**, Medical University of Innsbruck
Immune Senescence Drives Aortic Valve Calcification via $\gamma\delta$ T Cells
- 16 **Oskolkova Olga**, University of Graz
An immune assay for analysis of mechanisms neutralizing DAMPs generated by phospholipid oxidation
- 17 **Afonyushkin Taras**, Medical University of Vienna
High titres of IgM antibodies targeting oxidation-specific epitopes attenuate clonal hematopoiesis-associated cardiovascular risk
- 18 **Dube Twisha**, University of Graz
Exercise and NAD⁺ supplementation: A DUAL approach to cardiometabolic health
- 19 **Mair Katharina Sophia**, Medical University Vienna
Persistent macrophage activation despite effective lipid lowering in pediatric familial hypercholesterolemia

AMGEN

Lilly
A MEDICINE COMPANY

The logo for MSD consists of a green four-lobed shape resembling a cross with rounded ends, with white horizontal bars in the top and bottom lobes.
MSD

The logo for Novartis is a stylized blue and orange flame-like symbol.
NOVARTIS

The logo for sobi features an orange circle with three white dots arranged vertically.
sobi